Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2023-08-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve unaudited interim results for the six months ended 30 June 2023. It does not contain the actual interim financial report or detailed financial data, but merely announces the upcoming board meeting and the agenda to approve interim results. The document length is only 1296 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such short announcements about report approval dates are classified as Regulatory Filings (RNS) rather than the Interim Report (IR) itself, which would contain substantive financial data and analysis. Therefore, the correct classification is Regulatory Filings (RNS).
2023-08-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2023. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other agreements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital movements and share option details. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital movements and compliance with listing rules. The document length is about 5100 characters, and it is a formal regulatory return rather than a report or announcement of a report. Therefore, the best classification is Regulatory Filings (RNS).
2023-08-01 English
VOLUNTARY ANNOUNCEMENT - DESVENLAFAXINE SUCCINATE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a pharmaceutical product. It is a short announcement (2568 characters) and does not contain financial data, management discussion, or detailed report content. It is not an annual or interim report, earnings release, or any detailed financial or governance report. It is also not a regulatory filing in the sense of compliance or certification, nor a voting result or capital change. The content is an announcement of a significant business development (drug approval) but does not fit into categories like M&A, legal proceedings, or capital updates. Given the nature and length, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2023-07-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2023. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other agreements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital movements and share option details. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing related to share capital movements and share options, not a full financial report or announcement of voting results. The document length is about 5,097 characters, which is substantive but focused on share capital movements. Therefore, the best classification is Regulatory Filings (RNS), as it is a regulatory compliance document reporting share capital movements under exchange rules, not a financial report or announcement of voting results or capital changes like new share issues or buybacks.
2023-07-03 English
VOLUNTARY ANNOUNCEMENT - RABEPRAZOLE SODIUM ENTERIC-COATED TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a specific product. It is a short announcement (2386 characters) and does not contain financial data, financial statements, or detailed report content. It is not an annual report, earnings release, or any detailed financial or management report. It is also not a regulatory filing in the sense of compliance or certification, but rather a corporate announcement about product approval. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-07-03 English
VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION OF BATOCLIMAB (HBM9161) ACCEPTED BY THE NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the acceptance of a biologic license application by the National Medical Products Administration (NMPA) in China. It provides information about the product Batoclimab (HBM9161), its clinical trial results, and future development plans. The document is relatively short (2724 characters) and does not contain any financial statements, detailed financial data, or regulatory filings such as annual or interim reports. It is an announcement of a regulatory milestone related to product licensing rather than a financial or governance report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not related to board changes, voting results, or capital changes. Given the nature of the content and the voluntary announcement format, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.